Prof Frédérique Penault-Llorca, MD [7505]

What meaningful information with respect to actionable and validated genomic alterations are reported by FoundationOne and what is their translational value for selecting targeted therapies? (French) Video

What meaningful information with respect to actionable and validated genomic alterations are reported by FoundationOne and what is their translational value for selecting targeted therapies? (French)

What clinically meaningful and actionable information with respect to actionable and validated genomic alterations are reported by FoundationOne and what is their translational value for selecting targeted therapies in the setting of precision-focused ...
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, what percentage of patients will have actionable genomic alterations detected by NGS-based technologies? (French) Video

Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, what percentage of patients will have actionable genomic alterations detected by NGS-based technologies? (French)

Among such solid tumors as NSLC, melanoma, colorectal, and breast cancers, approximately what percentage of patients will have actionable genomic alterations—EGFR, ALK, HER-2, RAS, and others—that are detected by FoundationOne or other ...
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What is the evolving role of NGS-based assessment of genomic markers for treatment of colorectal cancer? (French) Video

What is the evolving role of NGS-based assessment of genomic markers for treatment of colorectal cancer? (French)

What is the evolving role of NGS-based assessment of genomic markers for treatment of colorectal cancer? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What information does the FoundationOne NGS assay and other methods provide on a tumor- and patient-specific basis? Coding sequence for cancer-related genes and exons? Introns from genes? (French) Video

What information does the FoundationOne NGS assay and other methods provide on a tumor- and patient-specific basis? Coding sequence for cancer-related genes and exons? Introns from genes? (French)

What precise information does the FoundationOne NGS assay and other commercially available genomic profiling methods provide on a tumor- and patient?specific basis? Coding sequence for how many cancer-related genes and exons? How many ...
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Since Hot Spot profiling is inadequate for detecting copy number alterations and rearrangements, which actionable tumor-specific targets are may be missed by Hot Spot as opposed CGP? (French) Video

Since Hot Spot profiling is inadequate for detecting copy number alterations and rearrangements, which actionable tumor-specific targets are may be missed by Hot Spot as opposed CGP? (French)

Since Hot Spot profiling is inadequate for detecting copy number alterations and rearrangements, which critical and actionable tumor-specific molecular targets are likely to be missed by Hot Spot profiling as opposed CGP? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

With respect to identifying critical genomic markers, how effective are single marker tests such as FISH and IHC? How many clinically relevant alterations can they identify? (French) Video

With respect to identifying critical genomic markers, how effective are single marker tests such as FISH and IHC? How many clinically relevant alterations can they identify? (French)

With respect to identifying critical genomic markers, how effective are standard single marker tests such as FISH and IHC, and hot spot panels? How many clinically relevant alterations are they able to identify? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What is the role of NGS in lung cancer? Can we follow mutational changes as the tumor evolves and what are the implications of longitudinal monitoring with NGS? (French) Video

What is the role of NGS in lung cancer? Can we follow mutational changes as the tumor evolves and what are the implications of longitudinal monitoring with NGS? (French)

What is the role of NGS in lung cancer? Can we follow mutational changes as the tumor evolves and what are the implications of longitudinal monitoring with NGS? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer? And what targeted agents does the NCCN recommend for these specific driver events? (French) Video

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer? And what targeted agents does the NCCN recommend for these specific driver events? (French)

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

Using FoundationONE NGS, what are the false-negative rates for EFGR? ALK rearrangement? What are the false-negative rates using hot spot NGS panels? (French) Video

Using FoundationONE NGS, what are the false-negative rates for EFGR? ALK rearrangement? What are the false-negative rates using hot spot NGS panels? (French)

Using FoundationONE NGS, what are the false-negative rates for EFGR? For an ALK rearrangement? What are the comparative false-negative rates using standard hot spot NGS panels? What explains the difference in the false-negative rates between ...
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What is the role of NGS in patients with metastatic disease and tumors of unknown origin? (French) Video

What is the role of NGS in patients with metastatic disease and tumors of unknown origin? (French)

What is the role of NGS in patients with metastatic disease and tumors of unknown origin? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD

What advances have we made employing NGS-based genomic profiling for gynecologic cancers, including ovarian cancer? (French) Video

What advances have we made employing NGS-based genomic profiling for gynecologic cancers, including ovarian cancer? (French)

What advances have we made employing NGS-based genomic profiling for gynecologic cancers, including ovarian cancer? (French)
Prof Frédérique Penault-Llorca, MD

Prof Frédérique Penault-Llorca, MD